# Vaccine Monitoring Platform (VMP) list of studies

Table 1. Studies funded by the European Medicines Agency for the Vaccine Monitoring Platform (VMP)

<table>
<thead>
<tr>
<th>Topic</th>
<th>Start date</th>
<th>Current status</th>
<th>HMA-EMA Catalogue</th>
<th>Title and description of the study</th>
<th>Countries</th>
</tr>
</thead>
</table>
| Safety | 06/04/2021  | Completed      | 49318             | Safety monitoring of COVID-19 vaccines in European countries  
This study is about understanding the side effects of the different COVID-19 vaccines. Vaccinated people report reactions to the vaccine through electronic questionnaires for up to 6 months after their first vaccine dose, contributing to a broader European understanding of the safety of these vaccines. | Belgium, Croatia, France, Germany, Italy, Luxembourg, Netherlands, United Kingdom |
| Safety | 06/04/2021  | Completed      | 47756             | Safety monitoring of COVID-19 vaccines in European countries  
This study is about understanding the side effects of the different COVID-19 vaccines in vulnerable people (pregnant/lactating women, children, immunocompromised, etc.). Vaccinated people report reactions to the vaccine through electronic questionnaires for up to 6 months after their first vaccine dose, contributing to a broader European understanding of the safety of these vaccines. | Ireland, Italy, Netherlands, Portugal, Romania, Slovakia, Spain, Switzerland |
| Safety | 06/04/2021  | Completed      | 50433 Published study | Readiness to investigate vaccine safety concerns  
The overall aim of this study is to create a network of electronic healthcare data source to be prepared to check if the COVID-19 vaccines are safe. Because it is a large network, even very rare side effects can be investigated. If a potential safety issue is signalled by researchers, regulators or clinicians, this network allows to quickly analyse the matter. For example, the network was used to explore the risk of myocarditis and pericarditis, contributing to generate additional results to support regulatory and public health decision making. | Belgium, Italy, Netherlands, Norway, Spain, United Kingdom |
| Safety | 28/09/2021  | Completed      | 46886             | Association between COVID-19 vaccines and thromboembolic events  
This study investigates the risk of rare blood clots in several large healthcare data sources by tracking people who have this problem and checks antibodies, reactions to vaccines, and safety for 12 months. | Spain, Netherlands, Germany, France, United Kingdom, United States |
<table>
<thead>
<tr>
<th>Vaccine Monitoring Platform (VMP) list of studies</th>
<th>EXT/92874/2024</th>
</tr>
</thead>
</table>
| **Effectiveness** 26/01/2022 Completed 48758 | Comparative effectiveness of heterologous and homologous primary- and booster SARS-CoV-2 vaccination schedules in the Nordic countries  
This study uses data from nationwide healthcare registries in Nordic countries to understand how well COVID-19 vaccines protect against mild or severe COVID-19, and how that protection changes over time. It also checks how mixing different vaccine brands impacts their protective effect. | Denmark, Finland, Norway, Sweden |
| **Effectiveness** 20/04/2022 Completed 50294 | Effectiveness of COVID-19 vaccination in European countries  
This study is about COVID-19 vaccines. It uses electronic health care data to understand how well COVID-19 vaccines protect against mild or severe COVID-19, and how that protection changes over time. | Italy, Netherlands, Spain, United Kingdom |
| **Safety** 03/08/2022 Completed 50201 | Association between COVID-19 vaccines and pediatric safety outcomes in children and adolescents aged 5-19 years in the Nordic countries  
This study is about COVID-19 vaccines in children. It uses electronic health care data to understand the safety in children and whether there is a link to immune-related conditions. | Denmark, Finland, Norway, Sweden |
| **Safety and effectiveness** 06/10/2022 Ongoing 50282 | Safety and Effectiveness of MVA-BN vaccination against MPXV infection in at-risk individuals in Germany  
This study is about Mpox vaccines. It collects data to understand if the vaccine lowers the risk of getting Mpox and how a person’s health condition influence that protection. | Germany |
| **Safety and effectiveness** 22/11/2022 Completed 105127 | Effectiveness and safety of MVA-BN vaccination against Mpox in at-risk individuals in the United States  
This study is about Mpox vaccines. It uses electronic health care data to understand how effective and safe it is for men who have sex with men and transgender women in the U.S. | United States |
| **Effectiveness** 01/08/2023 Completed 106559 | Effectiveness of bivalent Covid-19 booster vaccines in the Nordic countries 2023  
This study is about the adapted (bivalent) COVID-19 vaccines. It uses data from nationwide registries to understand how well the adapted COVID-19 vaccines protect against severe COVID-19 (including death from COVID-19), and how that protection changes over time. | Denmark, Finland, Norway, Sweden |
| **Effectiveness** 18/12/2023 Ongoing | Effectiveness of bivalent Covid-19 booster vaccines in the Nordic countries 2024  
This study is about the adapted (bivalent) COVID-19 vaccines. It uses data from nationwide registries to understand how well the adapted COVID-19 vaccines protect against severe COVID-19 (including death from COVID-19). It also looks at how that protection changes over time, explores the influence of coadministration with the flu vaccine, and analyses protection against the most recent COVID-19 variants. | Denmark, Finland, Sweden |
| **Safety** 07/02/2024 Ongoing | A framework for the post-authorisation safety evaluation of vaccines in the EU  
This project is about vaccines in general. It uses electronic health care data to create a network that can be used to check if vaccines are safe. Because it is a large network, even very rare events can be investigated. If a potential safety issue is signalled by researchers, regulators or clinicians, the data in this network can quickly analyse the matter. It also looks specifically at immunocompromised people. | |
| **Effectiveness** 27/07/2023 Ongoing 107616 | DARWIN EU® Effectiveness of COVID 19 vaccines on severe COVID 19 and post-acute outcomes of SARS-CoV-2 infection  
This study is about COVID-19 vaccines. It aims to understand the real-world effectiveness and duration of protection from COVID-19 vaccines in preventing severe outcomes, mortality, and complications. | United Kingdom, Spain, Netherlands |
<table>
<thead>
<tr>
<th>Disease burden</th>
<th>Date</th>
<th>Status</th>
<th>Study Title</th>
<th>Additional Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disease burden</td>
<td>15/09/2023</td>
<td>Ongoing</td>
<td>DARWIN EU® Age specific incidence rates of RSV related disease in Europe</td>
<td>This study is about the respiratory syncytial virus (RSV). It wants to understand how often people get infected with RSV, how often people are hospitalised for RSV, and how often people die from RSV. This information will help to understand vaccine safety and protection.</td>
</tr>
<tr>
<td>Effectiveness</td>
<td>02/10/2023</td>
<td>Ongoing</td>
<td>DARWIN EU® Effectiveness of Human Papillomavirus Vaccines (HPV) to prevent cervical cancer in women.</td>
<td>This study is about HPV vaccines. It wants to understand how effective they are in preventing severe outcomes like cervical cancer and advanced precancerous lesions. It assesses outcomes by vaccine brand, dose, and age group.</td>
</tr>
</tbody>
</table>

More information on these studies (for example reports and publications) can be found by clicking on the links in the column “HMA-EMA Catalogue”.

United Kingdom, Spain, Germany, France, Estonia